Back to Agenda
Session 3 Track B: Enhancing Patient Access Through the Access Continuum: Update and New Initiatives
Session Chair(s)
Samar Darwish, MBA, MSc
Director, Drug Regulatory Affairs
Boehringer Ingelheim, Canada
The four main steps of the access continuum start with Drug Development, HC regulatory review, HTA funding recommendation, and Provincial purchasing review and price negotiations. The time from HC granting of marketing authorization (MA) to drug plan coverage within the pan-Canadian Pharmaceutical Alliance (pCPA) process could take between 8 months to more than 2 years, and the HC-HTA alignment initiative was implemented in 2018 to minimize the time between HC MA and HTA recommendations. Its provision for voluntary opt-in by industry members to allow sharing of information has the potential to shorten the timeframe for HTA decision after HC approval by 180 days and would have an even bigger impact (~3-6 month saving) if the HTA decision could be issued at the same time as HC decision. This session will provide an update on this initiative from the HC, HTA and Industry perspective, as well as industry initiatives to introduce efficiency and predictability in the pCPA process.
Learning Objective : At the conclusion of this session, participants should be able to:
- Discuss the different elements affecting patient access to new drugs
- Describe benefits and challenges for HTA/HC aligned reviews
- Debate approaches to introduci efficiency and predictability in the pCPA process
Speaker(s)
Aligned reviews HC Experiences
Emile Geoffroy, MS
Health Canada, Canada
Manager, Plannng, Performance and Stakeholder Engagement Division
Aligned reviews HTA Experiences
Trevor Richter, PhD
CADTH, Canada
Director of Pharmaceutical Reviews
Speaker
Mandy Collier
Health Canada, Canada
Director, Health Products and Food Branch
Drug Access and Re-imbursement pCPA related initiatives
Joe Farago
Innovative Medicines Canada, Canada
Executive Director Private Markets and Innovation
Have an account?